OBJECTIVE: Previous studies suggest that hyperthyroid patients remain at increased risk of cardiovascular morbidity after restoring euthyroidism. The aim of this study was to compare the rate and causes of hospitalization of hyperthyroid patients treated with radioactive iodine (RAI) with those of an age- and gender-matched reference population in a long-term follow-up study. PATIENTS AND MEASUREMENTS: A population-based cohort study with a median follow-up time of 9 years was conducted among 2611 hyperthyroid patients treated with RAI between 1969 and 2002 in Tampere University Hospital, and among 2611 reference subjects. Information on hospitalizations was obtained from the nationwide Hospital Discharge Registry. New events were analysed as the main outcome, including only the first hospitalization due to a given indication. RESULTS: The rate of hospitalization due to cardiovascular disease (CVD) was higher among patients with hyperthyroidism than among the control population [637.1 vs. 476.4 per 10 000 person-years, rate ratio (RR) 1.12, 95% confidence interval (CI) 1.03-1.21]. The risk remained elevated up to 35 years after the RAI treatment. Hospitalizations due to atrial fibrillation (RR 1.35), cerebrovascular disease (RR 1.31), diseases of other arteries and veins (RR 1.22), hypertension (RR 1.20) and heart failure (RR 1.48) were more frequent in the patients than controls, while no such difference was found for coronary artery disease. Hospitalizations due to cancer, infectious and gastrointestinal diseases, and fractures were also more common in patients than in controls. CONCLUSIONS: Hyperthyroidism increases hospitalizations due to CVDs. The excess risk is sustained decades after treatment. Patients treated for hyperthyroidism constitute a high-risk group for CVD and may benefit from preventive interventions.
OBJECTIVE: Previous studies suggest that hyperthyroidpatients remain at increased risk of cardiovascular morbidity after restoring euthyroidism. The aim of this study was to compare the rate and causes of hospitalization of hyperthyroidpatients treated with radioactive iodine (RAI) with those of an age- and gender-matched reference population in a long-term follow-up study. PATIENTS AND MEASUREMENTS: A population-based cohort study with a median follow-up time of 9 years was conducted among 2611 hyperthyroidpatients treated with RAI between 1969 and 2002 in Tampere University Hospital, and among 2611 reference subjects. Information on hospitalizations was obtained from the nationwide Hospital Discharge Registry. New events were analysed as the main outcome, including only the first hospitalization due to a given indication. RESULTS: The rate of hospitalization due to cardiovascular disease (CVD) was higher among patients with hyperthyroidism than among the control population [637.1 vs. 476.4 per 10 000 person-years, rate ratio (RR) 1.12, 95% confidence interval (CI) 1.03-1.21]. The risk remained elevated up to 35 years after the RAI treatment. Hospitalizations due to atrial fibrillation (RR 1.35), cerebrovascular disease (RR 1.31), diseases of other arteries and veins (RR 1.22), hypertension (RR 1.20) and heart failure (RR 1.48) were more frequent in the patients than controls, while no such difference was found for coronary artery disease. Hospitalizations due to cancer, infectious and gastrointestinal diseases, and fractures were also more common in patients than in controls. CONCLUSIONS:Hyperthyroidism increases hospitalizations due to CVDs. The excess risk is sustained decades after treatment. Patients treated for hyperthyroidism constitute a high-risk group for CVD and may benefit from preventive interventions.
Authors: Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe Journal: J Clin Endocrinol Metab Date: 2018-07-01 Impact factor: 5.958
Authors: Christina Ellervik; Carolina Roselli; Ingrid E Christophersen; Alvaro Alonso; Maik Pietzner; Collen M Sitlani; Stella Trompet; Dan E Arking; Bastiaan Geelhoed; Xiuqing Guo; Marcus E Kleber; Henry J Lin; Honghuang Lin; Peter MacFarlane; Elizabeth Selvin; Christian Shaffer; Albert V Smith; Niek Verweij; Stefan Weiss; Anne R Cappola; Marcus Dörr; Vilmundur Gudnason; Susan Heckbert; Simon Mooijaart; Winfried März; Bruce M Psaty; Paul M Ridker; Dan Roden; David J Stott; Henry Völzke; Emelia J Benjamin; Graciela Delgado; Patrick Ellinor; Georg Homuth; Anna Köttgen; Johan W Jukema; Steven A Lubitz; Samia Mora; Michiel Rienstra; Jerome I Rotter; M Benjamin Shoemaker; Nona Sotoodehnia; Kent D Taylor; Pim van der Harst; Christine M Albert; Daniel I Chasman Journal: JAMA Cardiol Date: 2019-02-01 Impact factor: 14.676
Authors: Kyeong Jin Kim; Ji Eun Song; Ji Yoon Kim; Jae Hyun Bae; Nam Hoon Kim; Hye Jin Yoo; Hee Young Kim; Ji A Seo; Nan Hee Kim; Juneyoung Lee; Kyung Mook Choi; Sei Hyun Baik; Sin Gon Kim Journal: Ann Transl Med Date: 2020-10